The early diagnostic values of sDC-SIGN and sDC-SIGNR in stage I/II colon cancer patients.

Abstract

<p><b>A–B</b>: Both sDC-SIGN and sDC-SIGNR levels from early colon cancer patients. Stage I/II patients were significantly different from healthy people, P<0.01. sDC-SIGN is lower than in the healthy control, while sDC-SIGNR is higher. <b>C–D</b>: In the stage I/II patients, sDC-SIGN and sDC-SIGNR had a significant diagnostic value (P<0.01). The cut-off concentrations of DC-SIGN and DC-SIGNR were less than 2.211 µg/ml and more than 189.3 ng/ml, respectively. The corresponding sensitivity and specificity of the two molecules were 81.33% and 55.56%, 48.65% and 92.50%, respectively. <b>E–F</b>: The AUC of CEA and CA19-9 in early cancer were 0.6904 and 0.6917. At the above clinical decisive level, the sensitivity of both CEA (18.64) and CA19-9 (10.00) were very low, while, the specificity of both CEA (92.33) and CA19-9 (94.55) was high. <b>G</b>: The comparison between the ROC curves of four markers, DC-SIGN, DC-SIGNR, CEA and CA19-9. There were significant differences between the AUCs of sDC-SIGN and both sDC-SIGNR and CA19-9. According to the cut-off values for sDC-SIGN and sDC-SIGNR obtained from the ROC curves, CEA and CA19-9 from the clinical decisive level, the sensitivity (diagnostic values) of both sDC-SIGN (81%) and sDC-SIGNR (49%) were higher than CEA (19%) and CA19-9 (10%).</p

    Similar works

    Full text

    thumbnail-image

    Available Versions